Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB) and DNAstack launched the HiFi Solves Global Consortium to create the first global federated dataset of HiFi whole genome sequencing for rare disease research. The consortium spans nearly 30 institutions across 15 countries and has connected or committed to connect >b>10,000 HiFi whole genomes, enabling cross-border queries while data remain under local control.
The platform, hosted by DNAstack at hifisolves.org, supports secure federated queries, preserves data sovereignty, and leverages HiFi accuracy to improve detection of challenging variants and accelerate diagnoses for rare disease patients.
PacBio (NASDAQ: PACB) management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 2, 2026 at 2:30 PM ET in Boston.
A live webcast will be available on the company's investor site and a replay will be accessible for at least 30 days, according to PacBio.
PacBio (NASDAQ: PACB) reported Q4 and full‑year 2025 results for the period ended December 31, 2025. Q4 revenue was $44.6M (up 14% YoY) and FY revenue was $160.0M. Non‑GAAP gross margin improved to 40% in Q4 and FY 2025. The company completed the sale of short‑read assets for $48.1M net cash and ended the year with $279.5M in cash, cash equivalents, and investments.
Notable operational items included record consumables revenue, strong Vega system placements, reduced non‑GAAP operating expenses, and a GAAP net loss of $546.4M for FY 2025.
PacBio (NASDAQ: PACB) is joining the iHope global rare-disease genomics network as its first long-read sequencing partner to integrate HiFi long-read whole-genome sequencing.
iHope supports more than 1,000 patients annually across 25 clinical sites in 14 countries. Integration is expected to begin in early 2026 and aims to improve detection of challenging variants and support future precision-therapeutic research.
PacBio (NASDAQ: PACB) completed the sale of select short-read sequencing intellectual property and related assets to Illumina, closing January 30, 2026. PacBio received $48.1 million in net cash proceeds, Illumina assumed certain liabilities, and granted PacBio a non-exclusive license back to specified intellectual property.
PacBio said the transaction sharpens its focus on long-read sequencing, accelerates SPRQ-Nx chemistry development, and strengthens the company balance sheet.
PacBio (NASDAQ: PACB) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. A quarterly conference call and webcast will be held at 5:00 PM Eastern Time (2:00 PM Pacific) and will be accessible via PacBio's investor website.
Investors can listen live via the webcast or by phone: toll-free 1-888-349-0136 or international 1-412-317-0459. A replay will be available on the investor site after the call.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare to apply HiFi long‑read whole‑genome sequencing to support individualized antisense oligonucleotide (ASO) therapies for ultra‑rare genetic diseases. PacBio will donate sequencing reagents and provide scientific resources to enable variant phasing, structural variant detection, repeat expansion resolution, and regulatory‑grade molecular characterization to inform ASO target identification, design feasibility, and regulatory documentation. The collaboration aims to reduce sequential tests, accelerate target validation, and strengthen end‑to‑end genomics‑driven therapy development for n‑of‑1 patients.
PacBio (NASDAQ: PACB) announced on Jan 12, 2026 that a UW Medicine and Seattle Children’s research team will use HiFi whole-genome sequencing on PacBio Revio with SPRQ-Nx chemistry as a first-line approach to investigate Sudden Unexplained Death in Childhood (SUDC). The study will sequence trios from 200 families (child plus parents), prioritize long-read HiFi data for comprehensive variant detection, and join the HiFi Solves Global Consortium. The approach aims to simplify workflows for challenging inputs (post-mortem tissue, newborn dried blood spots) and to increase diagnostic yield by resolving structural variants, tandem repeats, and by identifying de novo versus inherited contributors to risk. PacBio provides in-kind support and the project is backed by the SUDC Foundation.
PacBio (NASDAQ: PACB) reported preliminary unaudited revenue of $44.6M for Q4 2025 (+14% YoY) and $160.0M for full year 2025 (+4% YoY).
Q4 drivers included higher Revio and Vega shipments and a record $21.6M in consumables revenue. Instrument revenue declined to $17.3M in Q4 and $53.8M for 2025 versus prior-year instrument revenue of $65.8M. Service and other revenue rose to $5.7M in Q4 and $24.3M for 2025.
System placements: Revio 21 in Q4 (61 for 2025) and Vega 42 in Q4 (140 for 2025). Ending cash, cash equivalents, and investments were about $279.5M. Results are preliminary and expected to be finalized in the 2025 Form 10-K and a February earnings call.
PacBio (NASDAQ: PACB) and UC Davis researchers introduced CiFi, a community-developed method that combines multi-contact chromatin conformation capture (3C) with PacBio HiFi long-read sequencing to produce chromosome-scale, haplotype-resolved assemblies from a single Revio sequencing run.
CiFi generates long, concatemeric HiFi reads that capture multiple chromatin interactions per molecule, improving mapping in repetitive regions, enabling multi-contact resolution, and reducing input material, libraries, and sequencing runs. A Nature Communications publication and demonstration on prairie and meadow vole produced uncurated assemblies with scaffold N50 values exceeding 100 million base pairs and telomeric sequence at many scaffold ends.